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14-3-3 proteins are important negative regulators of cell death pathways. Recent studies have revealed alterations in 14-3-3s in
Parkinson’s disease (PD) and the ability of 14-3-3s to interact with a-synuclein (a-syn), a protein central to PD pathophysiology.
In a transgenic a-syn mouse model, we found reduced expression of 14-3-3h,- e, and -c. These same isoforms prevent a-syn
inclusion formation in an H4 neuroglioma cell model. Using dopaminergic cell lines stably overexpressing each 14-3-3 isoform,
we found that overexpression of 14-3-3h,- e,o r- c led to resistance to both rotenone and 1-methyl-4-phenylpyridinium, whereas
other isoforms were not protective against both toxins. Inhibition of a single protective isoform, 14-3-3h, by shRNA did not
increase vulnerability to neurotoxic injury, but toxicity was enhanced by broad-based inhibition of 14-3-3 action with the peptide
inhibitor difopein. Using a transgenic C. elegans model of PD, we conﬁrmed the ability of both human 14-3-3h and a C. elegans
14-3-3 homologue (ftt-2) to protect dopaminergic neurons from a-syn toxicity. Collectively, these data show a strong
neuroprotective effect of enhanced 14-3-3 expression – particularly of the 14-3-3h,- e, and -c isoforms – in multiple cellular and
animal models of PD, and point to the potential value of these proteins in the development of neuroprotective therapies for
human PD.
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Parkinson’s disease (PD) is a neurodegenerative disorder
affecting more than four million older individuals in the
most populous nations.
1 There is currently no treatment that
slows the degenerative process. Although the cause of
most PD cases is unknown, substantial evidence points to a
central role of the protein a-synuclein (a-syn). Families with
point mutations or gene multiplication of a-syn exhibit
autosomal dominant PD.
2–6 In sporadic PD, a-syn aggregates
are present in Lewy bodies.
7,8 a-Syn overexpression in
cellular and animal models leads to cellular injury and
death,
9–12 but the mechanisms of this toxicity are poorly
understood.
In an effort to identify factors contributing to a-syn toxicity,
we have previously evaluated alterations in gene expression
in the substantia nigra (SN) of transgenic mice overexpres-
sing human wild-type a-syn.
13 We observed that among
alteredgenesare thoseencodingthe14-3-3proteins, afamily
of highly conserved proteins. There are seven mammalian
14-3-3 isoforms, comprising 1% of total brain protein, and
these proteins participate in many cellular functions by
mediating protein–protein interactions.
14,15 14-3-3s has a
central role in cell survival, and 14-3-3 depletion can lead to
activation of proapoptotic factors.
16
The observation that 14-3-3 expression was dysregulated
in a rodent model of a-syn overexpression was of particular
interest because of other evidence linking 14-3-3s to PD.
14-3-3s share structural homology with a-syn,
17 and co-
aggregate with a-syn in Lewy bodies in human PD
18 and in a
mouse PD model.
19 14-3-3 and a-syn can be co-immunopre-
cipitated from mammalian brains,
11,17 and co-immunopreci-
pitation is increased in PD brains.
20 14-3-3Z is a negative
regulator of the protein parkin,
20 mutation of which leads to
early onset PD.
21
Together, these observations support the hypothesis that
a-syn toxicity can arise from sequestration of 14-3-3 proteins,
disrupting cellular signaling, and liberating proapoptotic
factors. To test this hypothesis, we have examined the
expression of each 14-3-3 isoform in a-syn transgenic mice
and evaluated the effects of selective expression of the
different isoforms in PD cellular models and in an invertebrate
system. Our data reveal a potent and selective inhibition of
toxicity by a subset of the 14-3-3 isoforms: 14-3-3y,- e, and -g.
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14-3-3 isoform expression in a-syn transgenic mice. We
had previously examined changes in overall gene expression
in the SN of a-syn transgenic mice and found that distinct
14-3-3 isoforms were among the several hundred genes
whose expression was altered in this gene array study.
13 As
this mouse model yields most prominent a-syn pathology in
cortical neurons, we assessed the expression patterns of
14-3-3 isoforms in cortical homogenates from 3-month-old
transgenic mice, using quantitative PCR. We found that 14-3-
3y was the most signiﬁcantly downregulated isoform in the
cortex of the transgenic mice. This isoform was decreased by
nearly 50% in transgenic mice compared to wild-type mice
(Figure 1; Po0.05). 14-3-3g was reduced to 60% of wild type
(Po0.05). Expression of 14-3-3e and 14-3-3s trended down-
ward but did not reach statistical signiﬁcance (P¼0.072 for
14-3-3e; P¼0.088 for 14-3-3s).
14-3-3e,- c, and -h reduce a-syn inclusion forma-
tion. Because previous studies have revealed that a-syn
and 14-3-3s are colocalized in Lewy bodies, we asked
whether increased 14-3-3 expression could affect a-syn
aggregation. We used an in vitro a-syn inclusion body assay
developed by McLean et al.
22 Transfection of a-syn/truncated
green ﬂuorescent protein fusion (synT) with synphilin results
in cytoplasmic inclusions that immunostain for a-syn in about
50% of H4 neuroglioma cells (Figure 2). We co-transfected
H4 cells with either empty vector or a 14-3-3 isoform along
with synT and synphilin and immunostained cells against
a-syn 24h after transfection. 14-3-3e,- g, and -y reduced the
number of cells with a-syn inclusions by 40% compared to
control (Figure 2e; Po0.001). The other isoforms did not
affect a-syn inclusion formation. The reduction in inclusion
formation was not secondary to reduced a-syn expression,
as expression levels of synT were comparable between
control and 14-3-3y-transfected cells (Figure 2f). Levels
of endogenous monomeric a-syn were also not reduced in
14-3-3y-transfected cells (data not shown).
Creation of 14-3-3 stable cell lines. To examine directly
the potential neuroprotective properties of 14-3-3s, we
created stable cell lines overexpressing each 14-3-3
isoform. We subcloned cDNA clones for the 14-3-3
isoforms into the expression vector pcDNA3.1/V5-His. The
14-3-3 isoforms expressed from this vector are tagged with
V5 and His6 epitopes at the C-terminal end. SK-N-BE(2)-M17
(M17) dopaminergic cells were transfected with each 14-3-3
vector, and stable clones were selected in the presence of
G418. We created approximately 15–20 clones for each
isoform. Expression of the 14-3-3 proteins was assessed by
western blot analysis (Figure 3), and we chose 2–3 high-
expressing clones for the experiments described below. We
also created a control stable line by transfecting M17 cells
with the empty pcDNA3.1/V5-His plasmid.
14-3-3 overexpression in these stably transfected lines did
not affect the subcellular distribution of 14-3-3s. Immuno-
staining of naive M17 cells (Figure 4a) or control stable cells
(Figure 4b) with an antibody against 14-3-3y revealed a
predominantly cytoplasmic distribution. A similar distribution
was seen when we immunostained 14-3-3y-overexpressing
stablecellswitheitherthe14-3-3yantibody(Figure4c)oraV5
antibody (Figure 4f). Staining against 14-3-3e revealed similar
subcellular distribution of 14-3-3e in naive M17 and 14-3-3e-
overexpressing stable cells (data not shown). Subcellular
distributionofa-synwasalsonotalteredin14-3-3ystablecells
as compared to control cells (Figure 4g–j).
14-3-3h overexpression reduces rotenone toxicity.
Rotenone is a pesticide that induces a parkinsonian
syndrome in animals and reliably produces dose-dependent
a-syn aggregation and injury.
23,24 Because 14-3-3y was
the isoform most altered in the cortex of a-syn transgenic
mice, we ﬁrst assessed the effect of 14-3-3y on vulnerability
to rotenone. Control and 14-3-3y-overexpressing cells were
incubated with varying concentrations of rotenone in serum-
free DMEM for 24, 30, and 48h. Cell death was assayed by
lactate dehydrogenase (LDH) release into the culture media.
We found that rotenone produced dose-dependent
toxicity, and that 14-3-3y cells were more resistant to
rotenone than were control cells over a range of rotenone
doses and time points (Figure 5). The difference between
control and 14-3-3y cells was most prominent at 48h, when
cell death in response to 1mM rotenone in the 14-3-3y cells
was reduced to 45% of that in control cells (Figure 5c). We
conﬁrmed these ﬁndings with a second 14-3-3y clone
(Figure 5d).
As a control for artifacts that may have been introduced
during the selection of stable cell lines, we also examined the
effects of transient 14-3-3y transfection into naive M17 cells,
using transfection with EYFP for comparison. Because this
method leads to low rates of transfection, we used a different
approach to measure cell death. Cells were stained against
V5 or green ﬂuorescent protein (GFP) after the treatment
period, and cell injury was assessed by Hoechst 33342
staining (Invitrogen, Carlsbad, CA, USA). With the rater
masked to experimental condition, the nuclei of cells that
Figure 1 14-3-3 Expression in transgenic a-syn mice and wild-type littermates.
14-3-3y and g mRNA levels were signiﬁcantly reduced in a-syn transgenic mice
compared with wild-type mice. RNA was extracted from the cortex of 3-month-old
transgenic mice and wild-type littermates. Primers speciﬁc to each 14-3-3 isoform
were used for quantitative PCR to determine the amount of each 14-3-3 transcript.
Results were normalized to GAPDH. n¼8 per group. *Po0.05 (least-squares
means test). Error bar reﬂects S.E.M.
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Cell Death and Diseasestained for V5 or GFP were scored as normal or apoptotic.
Cells transiently transfected with 14-3-3y-overexpressing
cells showed decreased cell death in response to rotenone
(Figure 5e).
Given our results in the a-syn inclusion assay, we next
evaluated whether levels of insoluble a-syn were reduced in
14-3-3y cells as compared to control cells in response to
rotenone. Rotenone increases insoluble a-syn both in vitro
Figure 2 14-3-3e,- g, and -y reduce a-syn inclusions in H4 neuroglioma cells. (a–d) Immunocytochemistry of H4 cells transfected with synT, synphilin, and empty vector
(a, b) or 14-3-3y (c, d) with an antibody against a-syn and an Alexa 488-conjugated goat anti-mouse secondary antibody (green; a, c) or a pan-14-3-3 antibody and a cy-3-
conjugatedgoat anti-rabbit secondary antibody (red; b, d). Fewer cells transfected with 14-3-3y show a-syn inclusions as compared to control cells. Arrows point to cells with
a-syninclusions.Scalebar¼25mM.(e)H4cellswereco-transfectedwitheitheremptyvectorora14-3-3isoformalongwithsynTandsynphilin.At24haftertransfection,cells
wereﬁxedandstainedwith amonoclonal antibodyagainsta-syn.Cellsthatstainedfora-synwerescoredaspositiveornegativefora-syninclusions,withtheratermaskedto
experimental condition. Results reﬂect three independent experiments with four replicates per experiment. ***Po0.001 (Bonferroni’s multiple comparison test). Error bars
reﬂect S.E.M. (f) Expression levels of synT are not affected in H4 cells transfected with 14-3-3y. Representative western blot of total lysates from empty vector and 14-3-3y
transfected H4 cells incubated with an a-syn antibody is shown. Results were conﬁrmed in three independent experiments. Arrow points to the B32kDa a-syn/GFP fusion
protein (synT). Tubulin was used as a loading control
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Cell Death and Diseaseandinvivo.
23,24Wetreatedcontroland14-3-3ycellswith5mM
rotenone for 24h and then separated cell lysates into Triton
X-100 soluble and insoluble fractions. Upon rotenone treat-
ment, insoluble a-syn was dramatically increased in control
cells, whereas a muchsmaller increase in insoluble a-syn was
seen in 14-3-3y cells treated with rotenone (Figure 5f).
We next examined whether 14-3-3y reduction by lentiviral
shRNAs would result in increased rotenone toxicity to M17
cells. 14-3-3y shRNA lentiviruses signiﬁcantly reduced 14-3-
3y in M17 cells as compared to control virus with the empty
pLKO.1 vector (Supplementary Figure 1a). Cells infected with
14-3-3y shRNA did not show increased rotenone toxicity
compared to control cells (Supplementary Figure 1b). These
results were conﬁrmed using another 14-3-3y shRNA in the
same lentiviral construct (data not shown).
Differential effects of overexpression of 14-3-3 isoforms
on rotenone toxicity. Given the lack of increased rotenone
toxicity with 14-3-3y knockdown, we hypothesized that other
14-3-3 isoforms could compensate for the loss of 14-3-3y.
We decided to test whether overexpression of other 14-3-3
isoforms could protect against rotenone toxicity. We found
signiﬁcant differences between the different isoforms in
terms of their ability to protect against rotenone. Cells over-
expressing 14-3-3e and -g showed prominent reduction in
rotenone-induced toxicity (Figure 6a and b). Rotenone-
induced cell death at 1mM was reduced to 65 and 63%
of control in the 14-3-3e and 14-3-3g lines, respectively.
Overexpression of 14-3-3b and -z also provided some
protection, but not to the same extent as 14-3-3e,- g,o r- y
(Figure 6c and d). Rotenone-induced cell death at 1mM
was reduced to 70 and 78% of control levels in 14-3-3b and
14-3-3z cells, respectively. Differences in protection did not
correlate with 14-3-3 expression levels, as 14-3-3b cells
had higher V5 staining on western blots compared to 14-3-3e
and -y (Figure 3). Results for each isoform were conﬁrmed in
1–2 other cell clones overexpressing that isoform (data not
shown).
Overexpression of 14-3-3Z or -s did not provide protection
against rotenone at any doses tested (Figure 6e and f).
Instead, 14-3-3Z and 14-3-3s cells showed increased cell
death when maintained in serum-free media (Po0.01 and
o0.001, respectively) compared with control. In the presence
of rotenone, 14-3-3s cells showed increased toxicity com-
pared to control cells, although the difference between 14-3-
3s and control cells was less prominent. The 14-3-3Z cells
showed a nonsigniﬁcant trend toward increased toxicity in the
presence of rotenone compared to control cells. These
ﬁndings suggest that the 14-3-3Z and -s cells were more
sensitive to serum deprivation per se and that the over-
expression of these proteins does not confer any speciﬁc
resistance to rotenone. The results for 14-3-3Z and -s were
conﬁrmedin1–2othercellclonesoverexpressingthatisoform
(data not shown).
Difopein promotes rotenone toxicity. As several 14-3-3
isoforms are protective against rotenone, we next tested
whether a global competitive inhibitor of 14-3-3 function
would promote rotenone toxicity. Difopein, or dimeric,
fourteen-three-three peptide inhibitor, is a high-afﬁnity 14-3-
3 antagonist that disrupts 14-3-3/ligand interactions.
25
We subcloned the difopein-EYFP sequence into the
tetracycline-inducible lentiviral construct pSLIK
26 to allow
regulated induction of difopein, as it causes apoptosis at
baseline.
25 As the control, we subcloned the scrambled
difopein sequence with EYFP into pSLIK. M17 cells
were infected with either the difopein-EYFP lentivirus or the
control-EYFP lentivirus, and infected cells were selected in
the presence of hygromycin. Two days before treatment with
rotenone, selected cells were treated with 10mg/ml
doxycycline to induce difopein (or scrambled difopein)
expression, and then cells were incubated with rotenone for
30h. We found that cells expressing difopein showed
increased sensitivity to rotenone compared to control cells
(Figure 6g).
Figure 3 Stable M17 cells created to overexpress each 14-3-3 isoform. (a) 14-
3-3y was subcloned into the pcDNA3.1/V5-His vector, and SK-N-BE(2)-M17 cells
weretransfectedwithV5/His-tagged14-3-3yconstruct.Cellsstablytransfectedwith
14-3-3y were selected in the presence of G418. A total of 13 different clones were
analyzed for their expression of 14-3-3y. Protein lysates of these clones were
blotted with a monoclonal antibody against V5 to detect exogenous 14-3-3y (top
blot) or with a monoclonal antibody against 14-3-3y to detect total 14-3-3y levels
(exogenous or endogenous; bottom blot). Two clones (clones 4 and 5) with high
levels of 14-3-3y overexpression were used for the LDH experiments described
below. (b) 15–20 stable clones for each of the other 14-3-3 isoforms were similarly
created and analyzed for 14-3-3 overexpression by western blot against the V5
epitope tag. Two to three clones for each 14-3-3 isoform were selected for the LDH
experiments based on high expression levels. Western blots of these selected
clonesareshownusinganantibodyagainstV5.(c)Immunoblottingagainst14-3-3y
reveals higher expression level of 14-3-3y in 14-3-3y stable cell line clone 5 (Q5)
as compared to untransfected naive M17 cells (M17) and two control stable lines
(C1, C2). Tubulin was used as a loading control for all blots
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Cell Death and DiseaseDifferential effects of overexpression of 14-3-3 isoforms
on MPP
þ toxicity. We next tested whether the protective
effects of certain 14-3-3 isoforms were restricted to rotenone
or also effective against other neurotoxins that cause
parkinsonian syndromes in animals. 1-Methyl-4-phenyl-
pyridinium (MPP
þ) is the active metabolite of MPTP and
causes dose-dependent cell death in dopaminergic cell lines.
We tested the effects of MPP
þ on all seven cell lines. Once
again, 14-3-3y,- e, and -g overexpression reduced toxicity in
response to MPP
þ treatment for 24h (Figure 7a–c). 14-3-3b
and -z overexpression did not show any signiﬁcant protection
against MPP
þ (Figure 7d and e). 14-3-3Z and -s cells also
showed similar levels of cell death compared with control
cells in response to MPP
þ (Figure 7f and g). Once again,
these two sets of lines showed increased toxicity compared
to control cells in serum-free media in the absence of MPP
þ.
Effects of 14-3-3s on a-syn toxicity in vivo. Although both
rotenone and MPP
þ induce a-syn aggregation, we wished to
assess more directly the potential protective effects of 14-3-
3s against a-syn toxicity. We turned to a C. elegans model
of PD, in which human wild-type a-syn and GFP are
overexpressed in dopaminergic neurons under the control
of the dopamine transporter (dat-1) promoter. Transgenic
C. elegans overexpressing human wild-type a-syn show a
predictable loss of dopaminergic neurons as indicated by
Figure 4 Subcellular distribution of V5-tagged 14-3-3 isoforms and a-syn in stable cell lines was similar to endogenous expression in control M17 cells. (a–c) Naive M17
cells (a), control stable cells (b), and 14-3-3y-overexpressing cells (c) were immunostained using a primary monoclonal antibody against 14-3-3y and a cy-3-conjugated goat
anti-mouse secondary antibody to determine the cellular distribution of endogenous and overexpressed 14-3-3y. Cells were also stained with Sytox Green to localize nuclei.
14-3-3y Expression in all cells was seen predominantly in the cytoplasm. (d–f) These cell lines were also stained with a primary monoclonal antibody against V5 and a cy3-
conjugatedgoatanti-mousesecondaryantibodytodeterminethecellulardistributionofexogenousV5-tagged14-3-3y.V5stainingshowedsimilarcellulardistributionas14-3-
3yin14-3-3ystablecells(f).NoV5stainingwasapparentinM17(d)orcontrolstablecells(e).CellswerestainedwithSytoxGreentovisualizenuclei.(g–j)Controlcells(g,i)
and14-3-3ystablecells(h,j)werestainedwithanantibodyagainsta-syntodeterminesubcellularlocalizationofa-syn.Stainingwasapparentinbothnuclearandcytoplasmic
regions for both control (g) and 14-3-3y (h) cells. Sytox Green was used to stain nuclei (i, j). Scale bar¼30mM
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Cell Death and DiseaseFigure 5 Overexpression of 14-3-3y protects M17 cells from rotenone toxicity. (a–c) Cell lines stably transfected with either 14-3-3y or empty vector were treated with
varyingconcentrationsof rotenonefor 24h(a), 30h(b), or48h (c).Cell deathwas assayedby LDHreleaseintotheculturemedia. LDHreleaseintomedia wasnormalizedto
totalLDH releasefor each well. The14-3-3y-overexpressing line was more resistantto rotenone at severaldifferentconcentrations comparedto controlstablecells at all time
points tested. (d) At the 48h time point, a second 14-3-3y-overexpressing stable clone was tested to verify these results. Results reﬂect 2–3 independent experiments with at
least two replicates per experiment. *Po0.05, **Po0.01, ***Po0.001 (Bonferroni’s multiple comparison test). (e) To conﬁrm these ﬁndings using an alternative cell death
assay, we transiently transfected with V5/His-tagged 14-3-3y construct plasmid into naive M17 cells. Control cells were transfected with GFP. At 24h after transfection, cells
were treated with rotenone at 0, 0.2, or 1mM for 24h. Afterwards, cells were ﬁxed and immunostained with an antibody against V5 or GFP, followed by nuclear staining with
Hoechst 33342. Nuclei of transfected cells were scored as normal or showing apoptotic changes. Rater was blind to experimental condition. n¼8 for each experimental
condition. *Po0.05, ***Po0.001 (Bonferroni’s multiple comparison test). (f) Amount of insoluble a-syn was reduced in 14-3-3y cells treated with 5mM rotenone for 24h
compared to control cells. After rotenone treatment, cell lysates were separated into Triton X-100 soluble and insoluble fractions and blotted with an antibody against a-syn.
Representative westernblot of insoluble fractionsis shown. Densitometric quantiﬁcation of themultiple a-syn bands includesfourindependent experiments; we quantiﬁed the
region between B30 and B70kDa where all major bands were found. **Po0.01 (Tukey’s multiple comparison test). Error bars reﬂect S.E.M.
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Cell Death and DiseaseFigure6 Overexpressionofother14-3-3isoformsalsoprotectsagainstrotenonetoxicity,whereasinhibitionof14-3-3spromotestoxicity.(a–f)Celllinesstablytransfected
witheithera14-3-3isoformoremptyvectorweretreatedwithvaryingconcentrationsof rotenonefor48h.CelldeathwasassayedbyLDHreleaseinto theculturemedia.LDH
release into media was normalized to total LDH release for each well. Lines overexpressing 14-3-3e (a), 14-3-3g (b), 14-3-3b (c), or 14-3-3z (d) were more resistant to
rotenone compared to control stable cells. In contrast, overexpression of 14-3-3Z (e) and 14-3-3s (f) did not protect against rotenone and showed increased toxicity at
baseline. Resultsreﬂect 2–3independentexperiments with at leasttwo replicatesper experiment.*Po0.05, **Po0.01, ***Po0.001 (Bonferroni’s multiplecomparisontest).
Error bars reﬂect S.E.M. (g) M17cells were infectedwith either tetracycline-inducible difopein-EYFP lentivirusor scrambleddifopein-EYFPlentivirus.After 2 daysof induction
by doxycycline, cells were plated and treated with increasing doses of rotenone for 30h, and cell death was assayed by LDH release. Difopein-expressing cells were more
sensitive to rotenone compared to control stable cells. *Po0.05 (least-squares means test). Results reﬂect three independent experiments with at least two replicates per
experiment. Error bars reﬂect S.E.M.
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Cell Death and Diseasealterations in cellular morphology and reduction in GFP
expression.
27 We created double transgenic worms in which
a particular 14-3-3 isoform and a-syn were overexpressed,
both under the dat-1 promoter (Figure 8). Three separate
transgenic lines were created for each 14-3-3 isoform and
analyzed. We focused on 14-3-3e,- g, and -y, the three
Figure 7 Overexpression of 14-3-3e,- g, and -y protects against MPP
þ toxicity. Cell lines stably transfected with either a 14-3-3 isoform or an empty vector were treated
withvaryingconcentrationsofMPP
þ for24h.CelldeathwasassayedbyLDHreleaseintotheculturemedia.LDHreleaseintomediawasnormalizedtototalLDHreleasefor
eachwell.Linesoverexpressing14-3-3y(a),14-3-3e(b),or14-3-3g(c)weremoreresistanttoMPP
þ comparedtocontrolstablecells.Incontrast,overexpressionof14-3-3b
(d),14-3-3z(e),14-3-3Z(f),or14-3-3s(g)didnotprotectagainstMPP
þ.Resultsreﬂect2–3independentexperimentswithatleasttworeplicatesperexperiment.**Po0.01,
***Po0.001 (Bonferroni’s multiple comparison test). Error bars reﬂect S.E.M.
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Cell Death and DiseaseFigure 8 Overexpression of 14-3-3y protects against dopaminergiccell loss in the a-syn transgenicC. elegansworm model. Expression plasmids, Pdat 1H human14-3-
3yandPunc 54HmCherry,wereconstructedandmicroinjectedintothegonadsofC.elegansstrainthatalreadyexpressesa-synandGFP(Pdat 1Ha-syn;Pdat 1HGFP)and
exhibitsage-dependenta-syn-induceddegenerationindopaminergicneurons.Similardoubletransgenicwormswerecreatedtooverexpresshuman14-3-3e,human14-3-3g,
ortheworm14-3-3homologueftt-2.Inaddition,amutantftt-2knockoutthatoverexpresseda-synwasalsocreated.(a)a-Synwormshowslossofdopaminergicneurons(only
twoCEPneuronsandone ADEneuronremain) at day 7. Arrowheadsshowintact dopaminergic neuroncellbodies. Linedarrowsindicate areaswhere dopaminergic neurons
havedegenerated. (b) Overexpression of 14-3-3y in the a-syn-overexpressing line protectsdopaminergicneuronsfrom a-syn-inducedcell death.Arrowheadsshow sixintact
dopaminergic neuron cell bodies. (c, d) 14-3-3y reduced dopaminergic cell loss, but 14-3-3e and -g did not. Thenumbers of a-syn transgenicworms and a-syn/14-3-3double
transgenicworms thathad thefull complementof sixanterior dopaminergicneuronswere scoredat day 10 (c). Thepercentageof intactdopaminergicneuronsper wormwas
alsoscoredatday10fora-synanda-syn/14-3-3ytransgenicworms(d).(e,f)Overexpression(OE)oftheworm14-3-3homologueftt-2alsoreduceddopaminergiccelldeath,
but ftt-2 knockout did not enhance neurodegeneration. The percentage of worms that had the full complement of dopaminergic neurons (e) and the percentage of intact
dopaminergic neuronsper worm (f)werescoredat day 10.For eachexperiment,three independent transgeniclineswere scored,with 30 wormsper line analyzedin triplicate
experimental trials. Plotted data reﬂect the average of these three separate lines. ***Po0.001 (Bonferroni’s multiple comparison test). Error bars reﬂect standard deviation
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Cell Death and Diseasehuman isoforms that reduced neurotoxicity in response to
both rotenone and MPP
þ. In worms that overexpressed only
a-syn, we found that only 6.67% of the worms had all six
anterior dopaminergic neurons present at 10 days, whereas
13.61% of worms that overexpressed human 14-3-3y along
with a-syn had all six dopaminergic neurons at 10 days
(Figure 8c; Po0.001). Likewise, the average number of
intact dopaminergic neurons was signiﬁcantly higher in the
double transgenic 14-3-3y/a-syn worms compared to a-syn
worms (Figure 8d; Po0.001). Similar results were seen
when worms were analyzed at 7 days (data not shown).
Transgenic 14-3-3e or 14-3-3g worms did not exhibit a
signiﬁcant change in dopaminergic neurodegeneration
(Figure 8c).
We also investigated whether ftt-2, the closest C. elegans
homologue to 14-3-3y, can protect against a-syn toxicity. Of
transgenic worms that overexpress ftt-2 along with a-syn,
15.19% retained all six dopaminergic neurons, compared to
only 7.78% of a-syn worms, at 10 days (Figure 8e; Po0.001).
Average numbers of intact dopaminergic neurons were
signiﬁcantly higher in the ftt-2/a-syn double transgenic worms
compared to a-syn worms (Figure 8f; Po0.001). We also
tested whether knockout of ftt-2 affected a-syn toxicity. There
was no signiﬁcant difference in dopaminergic cell loss
between a-syn worms and a-syn/ftt-2 knockout worms at
10 days (Figure 8e and f). Semiquantitative RT-PCR was
used to conﬁrm lack of ftt-2 expression (data not shown).
Discussion
Using a diverse set of cellular and animal PD models, we
have observed a remarkably consistent neuroprotective
effect of several 14-3-3 isoforms. In a-syn transgenic mice,
we reportprominent mRNA downregulation of14-3-3e,-g,and
-y in the cortex, a site of intense a-syn pathology. We found
that these same isoforms reduce a-syn inclusions in neuro-
glioma cells and attenuate rotenone and MPP
þ toxicity in
stably transfected neuroblastoma cells. Both human 14-3-3y
anditswormhomologuereduceda-syntoxicityinaC.elegans
model. The effects of the other isoforms were less consistent:
14-3-3b and -z protected against rotenone but not MPP
þ,and
14-3-3Z and -s increased cell vulnerability to nonspeciﬁc
insults. The consistency of these results suggests common-
ality in the mechanism of protection in each of these assays,
and that the isoforms, although structurally similar, act on
different effector systems.
Further support for the speciﬁc relationship between 14-3-
3e,- g, and -y and PD pathophysiology is provided by studies
of Lewy bodies in human post-mortem brain. Using isoform-
speciﬁcantibodies,we observed 14-3-3e,-g,and -y,aswell as
14-3-3z in human Lewy bodies, whereas the other isoforms
were absent.
28 It should be noted that we were unable to
generate a 14-3-3z-overexpressing stable line that showed as
much overexpression as lines expressing other isoforms.
Therefore, it is possible that we failed to observe a broad
protectiveeffectof14-3-3zbecauseofinsufﬁcientexpression.
In addition, proteomic analysis of phosphorylation-dependent
a-syn interactions revealed that 14-3-3e,- g, and -z were
among those proteins that interact speciﬁcally with phos-
phorylated a-syn.
29
Although earlier studies have examined the effects of 14-3-
3 proteins in PD models, few have considered the differential
effects of all the distinct isoforms. One previous study showed
that 14-3-3e overexpression is protective against MPP
þ
toxicity in PC12 cells but did not evaluate other isoforms.
30
Studies showing interactions between 14-3-3s and a-syn
have not clearly deﬁned which isoforms are involved.
11,17
Sato et al.
20 provided the most extensive evaluation of
different 14-3-3 isoforms in an analysis of 14-3-3 effects on
parkin function. 14-3-3Z was the only isoform that immuno-
precipitated with parkin and inhibited its ubiquitylation activity.
We found that 14-3-3Z did not affect a-syn aggregation or
reduce neurotoxicity induced by rotenone or MPP
þ but
increasedsensitivitytoserum deprivation.As14-3-3Z reduces
parkin function, overexpression of 14-3-3Z could possibly be
detrimentaltocellsbyalteringproteindegradation.Thispoten-
tialmechanismdoesnotexplainour14-3-3sﬁndings,theother
isoform that promoted sensitivity to stressors, as 14-3-3s was
not found to bind parkin or alter its function.
20 14-3-3s has
been implicated as a tumor suppressor and is inactivated in
several cancers;
14,15,31,32 therefore, 14-3-3s overexpression
in cells examined by us could promote sensitivity to stressors
like serum deprivation. 14-3-3s expression is mainly limited
to epithelial cells
33 and is unlikely to be relevant to PD
pathogenesis.
Currently we do not know the mechanism for the differential
14-3-3 effects observed in our studies. The different isoforms
may bind to different ligands that mediate the differential
neuroprotective effects. An important ligand may be a-syn. As
noted above, a proteomic study showed that 14-3-3e,- g, and
-z interacted with a phosphorylated a-syn peptide, whereas
other isoforms were not detected.
29 Here we show that in
contrast to the other isoforms 14-3-3e,- g, and -y reduced
a-syn inclusion formation. We also observed less insoluble
a-syn in 14-3-3y cells treated with rotenone. Whether aggre-
gation is important to a-syn toxicity, the ability of these
isoforms to interact with a-syn may be key to their neuropro-
tective effects. Alternatively, the differential effects of 14-3-3s
may arise from differing abilities to interact with downstream
effectors. For example, 14-3-3e,- y, and -z interact with Bax,
whereas14-3-3bdoesnot.
34Differentialinteractionsof14-3-3
proteins with other apoptotic factors could also explain their
differential effects.
Although 14-3-3e,- g, and -y showed protection in vitro,
only human 14-3-3y overexpression reduced toxicity in the
C. elegans a-syn model. It is not clear why human 14-3-3e and
-g were not protective in this worm model. One explanation
is that 14-3-3y is more effective at reducing toxicity. Alter-
natively,C. elegans may not be able to process 14-3-3 isoforms
of a different species effectively. Human 14-3-3y is more
homologous with the C. elegans 14-3-3 orthologs than are
14-3-3e and -g. Indeed, we found that the worm 14-3-3
homologue ftt-2 was also effective in reducing a-syn toxicity.
It is also possible that only human 14-3-3y can effectively
interact with worm apoptotic factors.
In this study, we observed reduced RNA expression of
14-3-3e,- g, and -y in the a-syn transgenic mouse model.
Because these are the same isoforms that were protective
when overexpressed, this observation raises the possibility
that reduction of 14-3-3 expression may contribute to the
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reducing 14-3-3y mRNA levels directly through shRNA
inhibition, but found that inhibition of this single isoform
had no clear effect on vulnerability to rotenone. Similarly, ftt-2
knockout in the C. elegans model did not promote a-syn
toxicity. In both cases, other 14-3-3 isoforms could compen-
sate for the loss of a single 14-3-3 isoform – six others in
humans, and one other, par-5,i nC. elegans. We did observe
that the broad-spectrum 14-3-3 inhibitor, difopein, had a
modest effect on sensitivity to rotenone. There are several
potential explanations for the limited magnitude of this effect.
First, difopein expression levels could have been limited, as
higher levels are likely too toxic for cells to survive in control
conditions. Second, given the differential neuroprotective
effects of the 14-3-3s, the sum effect of interfering with all
isoforms may not be a dramatic increase in toxicity. We are
unable to test whether knockout of both ftt-2 and par-5 would
promote a-syn toxicity in the C. elegans model, as loss of
par-5 function is embryonically lethal.
35
We hypothesize that a-syn can disrupt 14-3-3 function
through several mechanisms that may contribute to a-syn
toxicity. Previously it has been suggested that the ability of
a-syn to sequester 14-3-3s would promote cell death by
release of apoptotic factors normally inhibited by 14-3-3s.
11
Weproposethata-synalsoexertsitseffectatatranscriptional
level to reduce the expression of functional 14-3-3 proteins:
decreased 14-3-3 transcription would compound effect of
a-syn on 14-3-3 sequestration by preventing injured neurons
from replenishing functional 14-3-3 stores. Functional geno-
mic analysis of our microarray data has shown that genes
whose expression is altered in a-syn transgenic mice are
predominantly involved in transcription.
13
Our data point to the potential therapeutic utility of treat-
ments that enhance 14-3-3 function or expression, especially
14-3-3e,- g, and -y. Several compounds that can stimulate
14-3-3 expression have been identiﬁed, including peroxi-
some proliferator-activated receptor-d (PPARd) and PPARg
ligands.
36–38 In a mouse stroke model, reduction of infarct
volume by rosiglitazone was blocked by siRNA knockdown of
14-3-3e and restored by increasing 14-3-3e.
38 The actions of
these compounds establish the principle that small molecules
can produce potent upregulation of 14-3-3 expression, and
point to the possibility of developing a useful human
neuroprotective agent that uses this mechanism.
Materials and Methods
Animals. a-Syn transgenic mice originally generated by Masliah et al.
39 were
bred at Charles River Laboratories (Wilmington, MA, USA) to generate transgenic
and wild-type littermates. The use of mice was supervised by the Massachusetts
General Hospital Animal Resources Program in accordance with the PHS
policy on Humane Care and Use of Laboratory Animals. Mice were killed by
CO2 inhalation. Gender-matched wild-type and transgenic mice were killed at
3 or 9 months of age.
Quantitative PCR. RNA was extracted from the cortex of wild-type and trans-
genic mice and reverse transcribed into ﬁrst-strand cDNA using the SuperScript II
Reverse Transcriptase Kit (Invitrogen). Primers against each of the human 14-3-3
isoforms were designed using Primer3 (http://frodo.wi.mit.edu). Primers against
14-3-3b (NM_018753)were 50-aaaggtcccgtgctcatacc-30 (forward)and 50-gccgcctca
acacattattc-30 (reverse). Primers against 14-3-3e (NM_009536) were 50-ttgggtgttag
cttgaggtg-30 (forward) and 50-gaggagtcggcaagaatgag-30 (reverse). Primers against
14-3-3g (NM_018871) were 50-tctgtgtcccgcttgtactg-30 (forward) and 50-aggcaggcac
acttctcaac-30 (reverse). Primers against 14-3-3Z (NM_011738) were 50-tctagcaaatc
caggtgatgg-30 (forward) and 50-aggctgatggtgaaggaatg-30 (reverse). Primers against
14-3-3y(NM_011739)were50-aggagtgacagcacacttgg-30 (forward)and50-gttgcttctg
aaaggaaacctc-30 (reverse). Primers against 14-3-3s (NM_018754) were 50-gtctgtcc
ttcatcgcagtc-30 (forward) and 50-tcctcgttgctcttctgctc-30 (reverse). Primers against
14-3-3z (NM_011740) were 50-ggctagtgattggaggaaacc-30 (forward) and 50-tcatatcg
ctctgcctgctc-30 (reverse). Real-time quantitative PCR was performed as previously
described.
13 We used GAPDH (forward primer 50-tggtgaagcaggcatctga-30; reverse
primer 50-tgctgttgaagtcgcaggag-30) to normalize PCR results.
a-Syn inclusion assay. H4 cells were transfected with synphilin, a-syn/synT,
and either empty vector control or a 14-3-3 isoform using SuperFect transfection
reagent (Qiagen, Germantown, MD, USA), as previously described.
22 At 24h after
transfection, cells were ﬁxed with 4% paraformaldehyde and immunostained with a
monoclonal antibody against a-syn (BD Biosciences, San Diego, CA, USA) and a
secondary Alexa 488-conjugated goat anti-mouse antibody (Invitrogen). All cells
stained for a-syn were scored as positive or negative for a-syn inclusions, with the
rater blind to experimental condition.
Creation of stable cell lines. Each 14-3-3 isoform was subcloned into the
mammalian expression vector pcDNA3.1/V5-His (Invitrogen). SK-N-BE(2)-M17
cells (ATCC, Manassas, VA, USA) were transfected with each isoform or empty
vector using SuperFect, and selection for stably transfected cells was performed in
the presence of G418 (Invitrogen). Some 15–20 clones for each isoform were
selected for evaluation of 14-3-3 expression by western blotting.
Immunoblotting. Control and 14-3-3 stable M17 cells were sonicated for 10s
on ice in lysis buffer (150mM NaCl, 10mM Tris-HCl (pH 7.4), 1mM EGTA, 1mM
EDTA,0.5%NP-40,proteaseinhibitorcocktail(RocheDiagnostics,Indianapolis,IN,
USA)) and centrifuged at 16000 g for 10min. Protein concentrations were
determined by the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Samples
were boiled for 5min in 4 DTT sample loading buffer (0.25M Tris-HCl (pH 6.8),
8% SDS, 200mM DTT, 30% glycerol, Bromophenol Blue), resolved on 15% SDS-
polyacrylamide gels, and transferred to PVDF membranes. Blots were blocked in
5% non-fat dry milk in TBST (25mM Tris-HCl (pH 7.6), 137mM NaCl, 0.1% Tween
20) for 1h, and then incubated overnight with primary mouse monoclonal antibody
against V5 (1:5000; Invitrogen), mouse monoclonal antibody against 14-3-3y
(1:10000; Abcam, Cambridge, MA, USA), or mouse monoclonal antibody against
a-tubulin (1:1000; Sigma, St Louis, MO, USA). After three washes in TBST, blots
were incubated with HRP-conjugated goat anti-mouse secondary antibody
(Jackson ImmunoResearch, West Grove, PA, USA) for 2h and then washed in
TBST six times for 10min each. Blots were developed with enhanced
chemiluminescence method (GE Healthcare, Piscataway, NJ, USA).
For a-syn blots of stable cell lines, cells were sonicated in lysis buffer (175mM
NaCl, 50mM Tris-HCl (pH 7.4), 5mM EDTA, protease inhibitor cocktail (Roche
Diagnostics)) and incubated with 1% Triton X-100 for 30min. After centrifugation,
thesupernatant wascollectedastheTritonX-100solublefraction.TheTritonX-100
insoluble fraction was prepared by resuspension of the pellet in lysis buffer with 2%
SDS.Sampleswereimmunoblottedasdescribedabove,usingamonoclonalanti-a-
syn antibody (1:1000; BD Biosciences). Densitometry was used to quantitate the
multiple a-syn bands (between B30 and 70kDa) in the insoluble fraction, which
were normalized to tubulin levels.
Immunocytochemistry. Naive M17 cells, control stable cells, and 14-3-3-
overexpressing stable cell clones were ﬁxed in 4% paraformaldehyde and
permeabilized with Triton X-100. After incubation with 1% normal goat serum, cells
were incubated overnight at 41C with a mouse monoclonal antibody against the V5
epitope tag (Invitrogen), a rabbit polyclonal antibody against 14-3-3e (Abcam), a
mouse monoclonal antibody against 14-3-3y (Abcam), or a rabbit polyclonal
antibody against a-syn (Cell Signaling, Danvers, MA, USA). Following washes in
TBS, cells were incubated with cy3-conjugated goat anti-mouse or anti-rabbit
secondaryantibody(JacksonImmunoResearch)for2hatroomtemperature.Nuclei
were stained with Sytox Green (Invitrogen).
LDH assay. Cells were grown in pyruvate-free DMEM for a few days before
plating in 24-well collagen-treated plates. The following day, cells were treated with
varying concentrations of rotenone (0, 0.04, 0.2, 1, 5, or 25mM; Sigma) or MPP
þ
(0, 2, 5, or 10mM; Sigma) in serum-free DMEM for 24, 30, or 48h. Toxicity was
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into media was normalized to total LDH release for each well.
RNA interference. The 14-3-3y shRNA pLKO.1 lentiviral constructs created
by The RNA Consortium were purchased from Open Biosystems (Huntsville, AL,
USA). Packaging of lentiviral shRNA constructs was performed by the UAB
Neuroscience NINDS Protein Core (P30 NS47466). Four shRNA constructs were
tested for their efﬁcacy in reducing 14-3-3y protein expression, and two constructs
were chosen for use in the rotenone toxicity experiments. M17 cells were infected
with the empty vector pLKO.1 virus or one of the two 14-3-3y shRNA-containing
pLKO.1 viruses in the presence of polybrene (Sigma). At 72h after infection,
infected cells were selected for in the presence of puromycin (Mediatech, Herndon,
VA, USA). Selected cells were used for rotenone toxicity experiments as described
under LDH assay.
Difopein experiments. Difopein-EYFP and scrambled difopein-EYFP
were subcloned into the tetracycline-inducible lentiviral vector pSLIK.
26 M17 cells
were infected with the difopein-EYFP or control-EYFP viruses in the presence of
polybrene. At 72h after infection, infected cells were selected for in the presence
of hygromycin (EMD Biosciences, Gibbstown, NJ, USA). Two days before rotenone
toxicity experiments, selected cells were treated with doxycycline (EMD
Biosciences) at 10mg/ml to induce difopein-EYFP or control-EYFP expression.
Generation and analysis of transgenic C. elegans. Expression
plasmids, Pdat 1H14-3-3y,P dat 1H14-3-3g,P dat 1H14-3-3e, and Pdat 1Hftt-2,
as well as a marker, Punc 54HmCherry, were constructed by Gateway Technology
(Invitrogen) and microinjected into the gonads of C. elegans strain UA44 (baIn11;
Pdat 1Ha-syn, Pdat 1Hgfp) that already expresses a-syn and GFP and exhibits
age-dependent a-syn-induced degeneration in the dopaminergic neurons.
27 Three
resulting independent transgenic lines for each strain UA113 (baIn11; baEx88,
Pdat 1H14-3-3y,P unc 54HmCherry), UA114 (baIn11; baEx89, Pdat 1H14-3-3g,
Punc 54HmCherry), UA115 (baIn11; baEx90, Pdat 1H 14-3-3e,P unc 54H
mCherry), and UA131 (baln11; baEx100,P dat 1Hftt-2,P unc 54HmCherry) were
synchronized, grown at 201C, and analyzed for neuroprotection at days 7 and 10
(4- and 7-day-old adults). For each trial, 30 worms were transferred onto a
2% agarose pad and immobilized with 3mM levamisole, and the six anterior
dopaminergic neurons (four CEP and two ADE dopaminergic neurons) were
examined. In total, 90 animals from each of three 14-3-3y, 14-3-3g, 14-3-3e, and
ftt-2, transgeniclines wereanalyzed(3 lines 3 trialsof 30 animals/trial¼270total
animals scored per 14-3-3 isoform). Worms displaying at least one degenerative
change were scored as exhibiting degenerating neurons, as previously
described.
27,40 The number of intact neurons per worm was also counted.
To study a ftt-2 loss of function mutant, C. elegans knockout strain MT14355
(ftt-2(n4426)) was crossed into strain UA44 (baIn11; Pdat 1Ha-syn, Pdat 1Hgfp)
to generate the isogenic strain UA130 (baln11; ftt-2(n4426)). This strain was
synchronized and analyzed as described above. Fluorescence microscopy was
performed using a Nikon Eclipse E800 epiﬂuorescence microscope equipped
withEndowGFPHYQﬁltercube(ChromaTechnology,Rockingham,VT,USA),and
images were captured with a Cool Snap CCD camera (Photometrics, Tucson, AZ,
USA) with MetaMorph software (Molecular Devices, Downingtown, PA, USA).
Statistical analysis. GraphPad Prism 5 (GraphPad Inc., La Jolla, CA, USA)
and SAS (SAS Inc., Cary, NC, USA) were used for statistical analysis of
experiments. Quantitative PCR data were analyzed by two-way ANOVA, followed
by post hoc least-squares means test. a-Syn aggregation experiments were
analyzed by one-way ANOVA, followed by post hoc Bonferroni’s multiple
comparison test. LDH assay experiments were analyzed by two-way ANOVA,
followed by post hoc Bonferroni’s multiple comparison test. a-Syn blots were
analyzed by one-way ANOVA, followed by post hoc Tukey’s multiple comparison
test. C. elegans data were analyzed by two-way ANOVA, followed by post hoc
Bonferroni’s multiple comparison test.
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